HomeCompareCTXRW vs EQR

CTXRW vs EQR: Dividend Comparison 2026

CTXRW yields 1387.93% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CTXRW wins by $346908156.06M in total portfolio value
10 years
CTXRW
CTXRW
● Live price
1387.93%
Share price
$0.14
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$346908156.10M
Annual income
$303,843,436,712,884.44
Full CTXRW calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — CTXRW vs EQR

📍 CTXRW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCTXRWEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CTXRW + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CTXRW pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTXRW
Annual income on $10K today (after 15% tax)
$117,973.63/yr
After 10yr DRIP, annual income (after tax)
$258,266,921,205,951.75/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, CTXRW beats the other by $258,266,921,202,705.10/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTXRW + EQR for your $10,000?

CTXRW: 50%EQR: 50%
100% EQR50/50100% CTXRW
Portfolio after 10yr
$173454078.07M
Annual income
$151,921,718,358,352.03/yr
Blended yield
87.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

CTXRW
No analyst data
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTXRW buys
0
EQR buys
0
No recent congressional trades found for CTXRW or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCTXRWEQR
Forward yield1387.93%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$346908156.10M$40.5K
Annual income after 10y$303,843,436,712,884.44$3,819.61
Total dividends collected$343747776.19M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CTXRW vs EQR ($10,000, DRIP)

YearCTXRW PortfolioCTXRW Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$149,493$138,792.51$11,248$547.57+$138.2KCTXRW
2$2,099,063$1,939,106.48$12,701$666.53+$2.09MCTXRW
3$27,692,262$25,446,263.94$14,405$814.59+$27.68MCTXRW
4$343,373,046$313,742,325.46$16,413$999.84+$343.36MCTXRW
5$4,003,185,043$3,635,775,884.26$18,795$1,232.92+$4003.17MCTXRW
6$43,897,781,482$39,614,373,485.65$21,639$1,527.95+$43897.76MCTXRW
7$452,951,824,425$405,981,198,239.62$25,057$1,903.80+$452951.80MCTXRW
8$4,399,656,810,870$3,914,998,358,735.43$29,197$2,385.87+$4399656.78MCTXRW
9$40,247,401,294,059$35,539,768,506,427.31$34,250$3,008.70+$40247401.26MCTXRW
10$346,908,156,097,527$303,843,436,712,884.44$40,467$3,819.61+$346908156.06MCTXRW

CTXRW vs EQR: Complete Analysis 2026

CTXRWStock

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Full CTXRW Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this CTXRW vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTXRW vs SCHDCTXRW vs JEPICTXRW vs OCTXRW vs KOCTXRW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.